Intended for healthcare professionals

Letters Bisphosphonates and gastrointestinal cancers

Authors’ reply to Abrahamsen and colleagues

BMJ 2013; 346 doi: (Published 12 March 2013) Cite this as: BMJ 2013;346:f1518
  1. Yana Vinogradova, research fellow in medical statistics1,
  2. Carol Coupland, associate professor and reader in medical statistics1,
  3. Julia Hippisley-Cox, professor of clinical epidemiology and general practice1
  1. 1Division of Primary Care, University Park, Nottingham NG2 7RD, UK
  1. yana.vinogradova{at}

Pazianas and colleagues’ study did show a 31% reduced risk of incident colorectal cancer in alendronate users compared with non-users (adjusted hazard ratio 0.69, 95% CI 0.60 to 0.79),1 2 as we noted.3 The alendronate group in table 2, however, included all women with one or more prescription for alendronate, and …

View Full Text

Log in

Log in through your institution


* For online subscription